View source for 18546081. MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 simplified abstract (The Regents of the University of California)

=MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Thomas J. Kipps of San Diego CA (US)|Thomas J. Kipps of San Diego CA (US)]][[Category:Thomas J. Kipps of San Diego CA (US)]]

[[:Category:Charles E. Prussak of San Diego CA (US)|Charles E. Prussak of San Diego CA (US)]][[Category:Charles E. Prussak of San Diego CA (US)]]

[[:Category:George F. Widhopf, Ii of San Diego CA (US)|George F. Widhopf, Ii of San Diego CA (US)]][[Category:George F. Widhopf, Ii of San Diego CA (US)]]

==MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18546081 titled 'MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1

==Simplified Explanation==

The abstract describes antibodies and antibody compositions that bind to human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity, useful for diagnosing and treating cancer and other ROR1-related diseases.

* Antibodies and antibody compositions target ROR1 with high efficiency and specificity.
* Include novel light and heavy chain domain CDRs and framework regions.
* Useful for diagnosing and treating cancer and ROR1-related diseases.

== Potential Applications ==
The technology can be applied in:
* Cancer diagnosis and treatment
* Targeted therapy for ROR1-related diseases

== Problems Solved ==
* Lack of specific targeting for ROR1 in cancer treatment
* Limited options for diagnosing and treating ROR1-related diseases

== Benefits ==
* Improved efficiency and specificity in targeting ROR1
* Potential for personalized medicine approaches

== Potential Commercial Applications ==
* Pharmaceutical companies for developing targeted therapies
* Diagnostic companies for cancer testing kits

== Possible Prior Art ==
There may be prior art related to:
* Antibodies targeting ROR1 in cancer therapy
* Diagnostic tools for ROR1-related diseases

== Unanswered Questions ==

=== How do these antibodies compare to existing ROR1-targeting therapies? ===
These antibodies may offer improved specificity and efficiency compared to current therapies, but further comparative studies are needed to confirm this.

=== What are the potential side effects of using these antibodies in cancer treatment? ===
The potential side effects of using these antibodies in cancer treatment need to be thoroughly investigated in clinical trials to ensure safety and efficacy.


==Original Abstract Submitted==

Provided herein are, inter alia, antibodies (e.g. humanized antibodies, monoclonal antibodies, antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR1-related diseases.



[[Category:C07K16/28]]
[[Category:A61K47/68]]
[[Category:A61P35/00]]
[[Category:G01N33/68]]